Liperial (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. This activation increases breakdown of triglyceride‑rich particles, reduces production of very‑low‑density lipoproteins, and modestly raises HDL‑cholesterol, leading to an overall improvement in the lipid profile.

The appropriate dose of Liperial is individualized by the prescribing clinician based on the patient’s specific lipid levels, renal and hepatic function, and any concomitant medications. Dosage adjustments are made according to clinical response and safety monitoring, not by a fixed over‑the‑counter regimen.

Safety data for fenofibrate during pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their healthcare provider.

To order Liparial, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to fenofibrate is another fibrate, gemfibrozil, or a high‑intensity statin. Fenofibrate tends to have a more favorable effect on HDL‑cholesterol and a lower risk of gallstone formation than gemfibrozil, while statins are more potent at lowering LDL‑cholesterol. Choice depends on the patient’s lipid profile and tolerance.

Liparial tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Liparial is taken orally, usually once daily with a meal to enhance absorption and reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless specifically directed by a healthcare professional.

The most serious adverse events include rhabdomyolysis (especially when combined with statins), severe liver injury, and acute pancreatitis. Patients should promptly report unexplained muscle pain, dark urine, jaundice, or severe abdominal pain, as early detection can prevent complications.

Liparial is contraindicated in patients with severe liver disease, active gallbladder disease, known hypersensitivity to fenofibrate or other fibrates, and in those with severe renal impairment (creatinine clearance <30 mL/min). Caution is also advised for individuals taking interacting medications such as gemfibrozil or high‑dose statins.